Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a clinical study titled ‘Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.’ The study aims to assess the safety and efficacy of epcoritamab in Japanese patients with relapsed or refractory B-cell lymphomas. This trial is significant as it explores a potential new treatment avenue for a challenging cancer type.
The trial is testing epcoritamab, a biological treatment administered subcutaneously, either as a monotherapy or in combination with standard-of-care (SOC) chemotherapy agents. The goal is to determine the maximum tolerated dose and recommended Phase-2 dose, as well as to evaluate its safety and efficacy.
The study is designed as a non-randomized, sequential assignment trial in Phase 1, followed by a parallel group assignment in Phase 2. It is an open-label study with no masking, focused on treatment as its primary purpose.
The study began on August 20, 2020, with a primary completion date yet to be disclosed. The latest update was submitted on August 4, 2025. These dates are crucial as they indicate the progress and current status of the trial.
This clinical update could positively impact AbbVie and Genmab’s stock performance, as successful results may enhance their market position in oncology. Investors should monitor competitor developments in the B-cell lymphoma treatment space to gauge potential market shifts.
The study is ongoing, with further details available on the ClinicalTrials portal.